Authors

  • Нажмутдинова Д.К., Махмадуллаева Ш.С.

Keywords:

синдром поликистозных яичников; мелатонин; C-реактивный белок; hs-CRP; хроническое воспаление; оксидативный стресс; инсулинорезистентность.

References

1. [1] Aboeldalyl S., James C., Seyam E., Ibrahim E.M., Shawki H.E.D., Amer S. The Role of Chronic Inflammation in Polycystic Ovarian Syndrome—A Systematic Review and Meta-Analysis. International Journal of Molecular Sciences. 2021;22(5):2734. doi:10.3390/ijms22052734.

2. [2] Akbari M., Ostadmohammadi V., Tabrizi R., Lankarani K.B., Heydari S.T., Amirani E. et al. The effects of melatonin supplementation on inflammatory markers among patients with metabolic syndrome or related disorders: a systematic review and meta-analysis of randomized controlled trials. Inflammopharmacology. 2018;26(4):899–907. doi:10. 1007/s10787-018-0508-7.

3. [3] Alizadeh M., Karandish M., Asghari Jafarabadi M., Heidari L., Nikbakht R., Babaahmadi Rezaei H. et al. Metabolic and hormonal effects of melatonin and/or magnesium supplementation in women with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial. Nutrition & Metabolism. 2021;18(1):57. doi:10.1186/s1 2986-021-00586-9.

4. [4] Armanini D., Boscaro M., Bordin L., Sabbadin C. Controversies in the Pathogenesis, Diagnosis and Treatment of PCOS: Focus on Insulin Resistance, Inflammation, and Hyperandrogenism. International Journal of Molecular Sciences. 2022;23(8):4110. doi:10.3390/ijms23084110.

5. [5] Cho J.H., Bhutani S., Kim C.H., Irwin M.R. Anti-inflammatory effects of melatonin: A systematic review and meta-analysis of clinical trials. Brain, Behavior, and Immunity. 2021; 93:245–253. doi: 10.10 16/j.bbi.2021.01.034.

6. [6] Evans A.T., Vanden Brink H., Lim J.S., Jarrett B.Y., Lin A.W., Lujan M.E., Hoeger K. Overnight Melatonin Concentration and Sleep Quality Are Associated with the Clinical Features of Polycystic Ovary Syndrome. Biomedicines. 2023;11(10):2763. doi:10. 3390/biomedicines11102763.

7. [7] González F. Inflammation in Polycystic Ovary Syndrome: Underpinning of Insulin Resistance and Ovarian Dysfunction. Steroids. 2012;77(4):300–305. doi: 10.1016/j.steroids.2011.12.003.

8. [8] González F., Rote N.S., Minium J., Kirwan J.P. Reactive oxygen species-induced oxidative stress in the development of insulin resistance and hyperandrogenism in polycystic ovary syndrome. The Journal of Clinical Endocrinology & Metabolism. 2006;91(1):336–340. doi:10.1210/jc.2005-1696.

9. [9] Jamilian M., Foroozanfard F., Mirhosseini N., Kavossian E., Aghadavod E., Bahmani F. et al. Effects of Melatonin Supplementation on Hormonal, Inflammatory, Genetic, and Oxidative Stress Parameters in Women with Polycystic Ovary Syndrome. Frontiers in Endocrinology. 2019; 10:273. doi:10. 3389/fendo.2019.00273.

10. [10] Kalyan S., Patel M.S., Kingwell E., Côté H.C.F., Liu D., Prior J.C. Assessing C reactive protein/albumin ratio as a new biomarker for polycystic ovary syndrome: a case-control study of women from a Canadian population. BMJ Open. 2018;8(10): e02 1860. doi:10.1136/bmjopen-2018-021860.

11. [11] Li H., Liu M., Zhang C. Women with polycystic ovary syndrome (PCOS) have reduced melatonin concentrations in their follicles and have mild sleep disturbances. BMC Women’s Health. 2022; 22:79. doi:10.1186/s12905-022-01661-w.

12. [12] Legro R.S., Arslanian S.A., Ehrmann D.A., Hoeger K.M., Murad M.H., Pasquali R., Welt C.K. Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline. The Journal of Clinical Endocrinology & Metabolism. 2013;98(12):4565–4592. doi:10.1210/jc.201 3-2350.

13. [13] Mojaverrostami S., Asghari N., Khamisabadi M., Heidari Khoei H. The role of melatonin in polycystic ovary syndrome: A review. International Journal of Reproductive BioMedicine. 2019; 17(12):865–882. doi:10.18502/ijrm.v17i12.5799.

14. [14] Mousavi R., Alizadeh M., Asghari Jafarabadi M., Heidari L., Nikbakht R., Babaahmadi Rezaei H. et al. Effects of melatonin and/or magnesium supplementation on biomarkers of inflammation and oxidative stress in women with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial. Biological Trace Element Research. 2022;200(3):1010–1019. doi:10.1007/s12011-021-02737-y.

15. [15] Pilehvari S., Moosavi M., Rezvanfar M.A., et al. The boosting effects of melatonin on the in vitro fertilization outcome in women with polycystic ovarian syndrome. Chonnam Medical Journal. 2023; 59(3):188–194. doi:10.4068/cmj.2023.59.3.188.

16. [16] Reiter R.J., Sharma R., Rosales-Corral S., de Almeida Chuffa L.G. Melatonin as a mitochondria-targeted antioxidant. Melatonin Research. 2024; 7(2):1–22. doi:10.32794/mr112500167.

17. [17] Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Human Reproduction. 2004;19(1):41–47. doi:10.10 93/humrep/deh098.

18. [18] Rudnicka E., Kunicki M., Calik-Ksepka A., Suchta K., Duszewska A.M., Smolarczyk K., Smolarczyk R. Chronic Low Grade Inflammation in Pathogenesis of PCOS. International Journal of Molecular Sciences. 2021;22(7):3789. doi:10.3390/ijms2207 3789.

19. [19] Rudnicka E., Duszewska A.M., Kucharski M., Tyczynski P., Smolarczyk R. Oxidative stress and reproductive function: oxidative stress in polycystic ovary syndrome. Reproduction. 2022; 164(6): F145–F154. doi:10.1530/REP-22-0152.

20. [20] Sánchez A., Calpena A.C., Clares B. Evaluating the Oxidative Stress in Inflammation: Role of Melatonin. International Journal of Molecular Sciences. 2015;16(8):16981–17004. doi:10.3390/ijms 160816981.

21. [21] Shabani A., Foroozanfard F., Kavossian E., Aghadavod E., Ostadmohammadi V., Reiter R.J., Asemi Z. Effects of melatonin administration on mental health parameters, metabolic and genetic profiles in women with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial. Journal of Affective Disorders. 2019;250:51–56. doi: 10.1016/j.jad.2019.02.066.

22. [22] Tagliaferri V., Romualdi D., Scarinci E., De Cicco S., Florio C.D., Immediata V. et al. Melatonin Treatment May Be Able to Restore Menstrual Cyclicity in Women with PCOS: A Pilot Study. Reproductive Sciences. 2018;25(2):269–275. doi:10.1177/19 33719117711262.

23. [23] Teede H.J., Tay C.T., Laven J.J.E., Dokras A., Moran L.J., Piltonen T.T. et al. Recommendations from the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. The Journal of Clinical Endocrinology & Metabolism. 2023;108(10):2447–2469. doi:10.1210/clinem/dgad463.

24. [24] Wang L., Zhang Y., et al. Effects of melatonin in polycystic ovary syndrome. Journal of Ovarian Research. 2025;18:65. doi:10.1186/s13048-025-01642-1.

25. [25] Ziaei S., Heshmati J., et al. Effect of melatonin supplementation on cardiometabolic risk factors, oxidative stress and hormonal profile in women with polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials. Journal of Ovarian Research. 2024;17:118. doi:10.11 86/s13048-024-01450-z.